Table 1 Baseline characteristics of patients and CVC characteristics of first line
All | Taurolidinea | High- concentrated citrate | Low-concentrated citrate | |
|---|---|---|---|---|
N (%) | 1514 | 96 (6) | 1110 (73) | 308 (20) |
Age (median, IQR) | 65 (53–74) | 58 (42–69) | 66 (54–75) | 63 (53–73) |
Male gender (%) | 893 (59) | 59 (61) | 649 (58) | 185 (60) |
Days of CVC in situ (median, IQR) | 37 (11–120) | 102 (27–210) | 35 (9–112) | 35 (13–118) |
Acute start of dialysis (%) | 605 (40) | 30 (31) | 421 (38) | 154 (50) |
History of diabetes mellitus (%) | 555 (37) | 34 (35) | 421 (38) | 100 (32) |
Use of immunosuppressive medication (%) | 411 (27) | 21 (22) | 296 (27) | 94 (31) |
Type of CVC (%) | ||||
Tunneled | 404 (27) | 39 (41) | 301 (27) | 64 (21) |
Non-tunneled, precurved | 624 (41) | 51 (53) | 459 (41) | 114 (37) |
Non-tunneled, straight | 461 (30) | 6 (6) | 330 (30) | 125 (41) |
Concentration lock (%) | ||||
4% | 55 (4) | – | – | 55 (18) |
30% | 253 (17) | – | – | 253 (82) |
46.7% | 1110 (73) | – | 1110 (100) | – |
Insertion site (%) | ||||
Jugular | 1182 (78) | 89 (93) | 862 (78) | 231 (75) |
Subclavian | 37 (2) | 4 (4) | 27 (2) | 6 (2) |
Femoral | 276 (18) | 3 (3) | 205 (18) | 68 (22) |
CVC lumen > 14 fr (%) | 675 (45) | 36 (38) | 484 (44) | 155 (50) |
Removal of CVC due to infection (%) | 156 (10) | 6 (6) | 120 (11) | 30 (10) |
Removal of CVC due to patency problem (%) | 163 (11) | 6 (6) | 119 (11) | 38 (12) |
Death (%) | 407 (27) | 24 (25) | 329 (30) | 54 (18) |
due to (any) infection | 83 (5) | 4 (4) | 62 (6) | 17 (6) |
cessation of dialysis | 108 (7) | 1 (1) | 93 (8) | 14 (5) |